Home › Research › Getting a diagnosis
Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease
Maass A, Landau S, Baker SL, Horng A, Lockhart SN, La Joie R, Rabinovici GD, Jagust WJ et al.. NeuroImage, 2017-06-03
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
The recent development of tau-specific positron emission tomography (PET) tracers enables in vivo quantification of regional tau pathology, one of the key lesions in Alzheimer's disease (AD). Tau PET imaging may become a useful biomarker for clinical diagnosis and tracking of disease progression but there is no consensus yet on how tau PET signal is best quantified. The goal of the current study was to evaluate multiple whole-brain and region-specific approaches to detect clinically relevant tau PET signal. Two independent cohorts of cognitively normal adults and amyloid-positive (Aβ + ) patients with mild cognitive impairment (MCI) or AD-dementia underwent [ 18 F]AV-1451 PET. Methods for tau tracer quantification included: (i) in vivo Braak staging, (ii) regional uptake in Braak composite regions, (iii) several whole-brain measures of tracer uptake, (iv) regional uptake in AD-vulnerable voxels, and (v) uptake in a priori defined regions. Receiver operating curves characterized accuracy in distinguishing Aβ - controls from AD/MCI patients and yielded tau positivity cutoffs. Clinical relevance of tau PET measures was assessed by regressions against cognition and MR imaging measures. Key tracer uptake patterns were identified by a factor analysis and voxel-wise contrasts. Braak staging, global and region-specific tau measures yielded similar diagnostic accuracies, which differed between cohorts. While all tau measures were related to amyloid and global cognition, memory and hippocampal/entorhinal volume/thickness were associated with regional tracer retention in the medial temporal lobe. Key regions of tau accumulation included medial temporal and inferior/middle temporal regions, retrosplenial cortex, and banks of the superior temporal sulcus. Our data indicate that whole-brain tau PET measures might be adequate biomarkers to detect AD-related tau pathology. However, regional measures covering AD-vulnerable regions may increase sensitivity to early tau PET signal, atrophy and memory decline.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Maass, A., Landau, S., Baker, S. L., Horng, A., Lockhart, S. N., La Joie, R., et al. (2017). Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease. NeuroImage. https://doi.org/10.1016/j.neuroimage.2017.05.058
Vancouver
Maass A, Landau S, Baker SL, Horng A, Lockhart SN, La Joie R, et al. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease. NeuroImage. 2017. doi:10.1016/j.neuroimage.2017.05.058. PMID: 28587897.
BibTeX
@article{maass2017-28587897,
author = {Maass, A. and Landau, S. and Baker, S. L. and Horng, A. and Lockhart, S. N. and La Joie, R. and Rabinovici, G. D. and Jagust, W. J. and others},
title = {{Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease}},
journal = {NeuroImage},
year = {2017},
doi = {10.1016/j.neuroimage.2017.05.058},
pmid = {28587897},
url = {https://doi.org/10.1016/j.neuroimage.2017.05.058}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- While all tau measures were related to amyloid and global cognition, memory and hippocampal/entorhinal volume/thickness were associated with regional tracer retention in the medial temporal lobe.
- Our data indicate that whole-brain tau PET measures might be adequate biomarkers to detect AD-related tau pathology.
Why it matters
In two separate groups of cognitively normal adults and amyloid-positive people with mild cognitive impairment or Alzheimer's dementia, researchers scored the same tau PET scans ([18F]AV-1451) five ways, from whole-brain averages to Braak-stage regions, and found the methods "yielded similar diagnostic accuracies, which differed between cohorts." The authors conclude whole-brain measures "might be adequate" to detect Alzheimer's-related tau, but that "regional measures covering AD-vulnerable regions may increase sensitivity to early tau PET signal, atrophy and memory decline." It is a single-scan comparison of measurement methods with no sample sizes or accuracy figures in this record, and it does not test any treatment or prevention.
New to this subject? Start with our plain-English guide: Getting a diagnosis →
Study details
- Evidence strengthLow
How this study scored 56/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (NeuroImage) |
| Journal's citation record | 4 / 4 | NeuroImage: journal h-index 523 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2017 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 462 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 42.0 citations a year over 11 year(s) since 2017 |
| Impact for its field and year | 5 / 6 | Cited 30.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 54 other studies in this library |
| Still being cited | 3 / 4 | Cited 131 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author William J. Jagust: h-index 152 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of California, Berkeley: institution h-index 2,012 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 28587897) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 56 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.neuroimage.2017.05.058
- PubMed: 28587897
- Original source →
- Free full text: NeuroImage →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 36.
Later studies that cite this one
54 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Getting a diagnosis from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.